GLAXOSMITHKLINE PLC Form 6-K October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

-			
Tranc	noction	notit	ication
	SACHOH	11()[]	ivalion

Details of PDMR/person closely associated with them ('PCA')
 Name Sir Andrew Witty
 Position/status Chief Executive Officer

Initial notification/

c) amendment

a)

d)

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends

b) Nature of the transaction re-investment of dividends paid to shareholders on 13

October 2016.

c)  $\frac{\text{Price(s)}}{\text{and volume(s)}}$   $\frac{\text{Price(s)}}{\text{£17.0319}}$   $\frac{\text{Volume(s)}}{25.344}$ 

Aggregated information
Aggregated volume Price

n/a (single transaction)

e) Date of the transaction 2016-10-13

Date of the transaction 2010 10 15

f) Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor President, Global

b) Position/status

Manufacturing & Supply

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary

Shares following the re-investment of dividends

paid to shareholders on 13

October 2016.

Price(s) Price(s) Volume(s) c) and volume(s) £17.0319 30.656

Aggregated information n/a (single transaction) Aggregated volume Price

e) Date of the transaction 2016-10-13

London Stock Exchange f) Place of the transaction

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Name Mr L Debruyne a)

Position/status President, Global Vaccines b)

Initial notification/ Initial notification

c) amendment

Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor

Name GlaxoSmithKline plc a)

LEI 5493000HZTVUYLO1D793 b)

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of the financial instrument each ('Ordinary Shares') a)

> ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the

Nature of the transaction re-investment of dividends b)

paid to shareholders on 13

October 2016.

Price(s) Price(s) Volume(s) c) £17.0319 645.478 and volume(s)

Aggregated information

d)

n/a (single transaction) Aggregated volume Price

Date of the transaction 2016-10-13 e)

London Stock Exchange Place of the transaction f)

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr S Dingemans a) Name

b) Position/status Chief Financial Officer

Initial notification/ Initial notification c) amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the re-investment of dividends

b) Nature of the transaction

paid to shareholders on 13

October 2016.

Price(s) Price(s) Volume(s) and volume(s) £17.0319 111.076

Aggregated information n/a (single transaction) Aggregated volume Price

e) Date of the transaction 2016-10-13

London Stock Exchange f) Place of the transaction

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain President, Global Position/status b) Pharmaceuticals

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor

Name GlaxoSmithKline plc a)

LEI 5493000HZTVUYLO1D793 b) Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each 3.

place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of the financial instrument each ('Ordinary Shares') a)

> ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the

Nature of the transaction re-investment of dividends b)

paid to shareholders on 13

October 2016.

Price(s) Price(s) Volume(s) c) £17.0319 589.664 and volume(s)

Aggregated information n/a (single transaction) d) Aggregated volume Price

Date of the transaction 2016-10-13 e)

London Stock Exchange

Place of the transaction f) (XLON)

1. a) b) c)	Details of PDMR/person closely associated Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	Mr D S Redfern Chief Strategy Officer Initial notification	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.	
a)	Price(s)	Price(s) Volume(s)	
c)	and volume(s)	£17.0319 921.902	
d)	Aggregated information	n/a (single transaction)	
	Aggregated volume Price Date of the transaction	2016-10-13	
e) f)	Place of the transaction	London Stock Exchange (XLON)	
1. a) b)	Details of PDMR/person closely associated Name Position/status Initial notification/	ated with them ('PCA') Ms C Thomas SVP, HR	
c)	amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares following the	
b)	Nature of the transaction	re-investment of dividends paid to shareholders on 13 October 2016.	

Price(s) Price(s) Volume(s) c) £17.0319 127.956 and volume(s) Aggregated information d) n/a (single transaction) Aggregated volume Price Date of the transaction 2016-10-13 e) London Stock Exchange Place of the transaction f) (XLON) Details of PDMR/person closely associated with them ('PCA') 1. Mr P C Thomson Name a) SVP. Communications & Position/status b) **Government Affairs** Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor Name GlaxoSmithKline plc a) 5493000HZTVUYLO1D793 LEI b) Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each 3. place where transaction(s) has been conducted Ordinary shares of 25 pence Description of the financial instrument each ('Ordinary Shares') a) ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 13 October 2016. Price(s) Price(s) Volume(s) c) and volume(s) £17.0319 413.464 Aggregated information n/a (single transaction) d) Aggregated volume Price Date of the transaction 2016-10-13 e) London Stock Exchange f) Place of the transaction (XLON) Details of PDMR/person closely associated with them ('PCA') 1. Name Dr M M Slaoui a) Chairman, Global Vaccines Position/status b) Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor Name GlaxoSmithKline plc a) 5493000HZTVUYLO1D793 LEI b) 3.

n/a (single transaction)

London Stock Exchange

2016-10-13

(XLON)

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	place where transaction(s) has been con	ducted	
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
	•	ISIN: GB0009252882	
		Acquisition of Ordinary	
		Shares following the	
b)	Nature of the transaction	re-investment of dividends	
U)	reaction are transaction	paid to shareholders on 13	
		October 2016.	
	Dui (-)		
c)	Price(s)	Price(s) Volume(s)	
,	and volume(s)	£17.0319 1.905	
d)	Aggregated information	n/a (single transaction)	
۵)	Aggregated volume Price		
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange	
1)	Tace of the transaction	(XLON)	
1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr P J T Vallance	
1. \	Decition later	President, Pharmaceuticals	
b)	Position/status	R&D	
	Initial notification/	Initial notification	
c)	amendment		
2	Details of the issuer, emission allowance	e market participant, auction	
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
-,	Details of the transaction(s): section to		
3.	instrument; (ii) each type of transaction	_	
٥.	place where transaction(s) has been con		
	place where transaction(s) has been con	Ordinary shares of 25 pence	
a)	Description of the financial instrument	•	
a)	Description of the financial institution	ISIN: GB0009252882	
		Acquisition of Ordinary	
• `	N. Cal	Shares following the	
b)	Nature of the transaction	re-investment of dividends	
		paid to shareholders on 13	
		October 2016.	
c)	Price(s)	Price(s) Volume(s)	
C)	and volume(s)	£17.0319 1545.793	

Aggregated information

Place of the transaction

Aggregated volume Price Date of the transaction

d)

e)

f)

1. a) b) c)	Details of PDMR/person closely associated Name Position/status Initial notification/	Ms E Walmsley CEO Designate Initial notification	
2.	amendment  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £17.0319 1211.674	
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	
1. a)	Details of PDMR/person closely associated with them ('PCA') Name Mrs K Thomson		
b)	Position/status	PCA of Mr P C Thomson (SVP, Communications & Government Affairs)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends	

paid to shareholders on 13

October 2016.

Price(s) Volume(s) £17.0319 101.411

n/a (single transaction)

2016-10-13

London Stock Exchange

(XLON)

## **SIGNATURES**

c)

d)

e)

f)

Price(s)

and volume(s)

Aggregated information

Place of the transaction

Aggregated volume Price Date of the transaction

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 $GlaxoSmithKline\ plc$ 

(Registrant)

Date: October 17, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc